Nine Diagnostics, a leader in AI-enabled nanosensor technology, has been selected to participate in the American Cancer Society’s BrightEdge Entrepreneurs Program, a highly selective initiative designed to accelerate promising and high-impact oncology-focused startups. This selection marks another significant milestone for Nine Diagnostics as it continues to drive innovation in cancer treatment selection, dosing, optimization, and monitoring.
The BrightEdge Entrepreneurs Program is a highly competitive initiative that provides selected startups with access to top-tier mentorship, investment opportunities, and strategic industry connections. By integrating Nine Diagnostics into this network, BrightEdge will help support the company’s potential to transform cancer diagnostics through advanced AI and novel nanosensor technology. Through the program, Nine Diagnostics will benefit from expert guidance, direct engagement with oncology thought leaders, and opportunities to scale its technology in collaboration with leading institutions and investors. The company is poised to leverage these resources to further its mission of transforming early cancer detection and improving patient outcomes worldwide.
“Joining the BrightEdge Entrepreneurs Program is a tremendous opportunity for Nine Diagnostics,” said Freddy T. Nguyen, MD, PhD, Co-Founder and CEO of Nine Diagnostics. “This recognition validates our vision and the potential impact of our AI-enabled nanosensor technology. With the support of BrightEdge, we are positioned to accelerate our innovations and bring meaningful solutions to the fight against cancer.”
Daniel A. Heller, PhD, Co-Founder and CSO of Nine Diagnostics, added, “Access to BrightEdge’s extensive network of healthcare leaders, investors, and research institutions will be invaluable as we continue to scale our platform. We are committed to advancing cutting-edge solutions that enhance cancer diagnostics, and this program brings us one step closer to making a meaningful impact in global oncology care.”
BrightEdge is the innovation and impact investment arm of the American Cancer Society (ACS), dedicated to fostering high-potential startups developing breakthrough solutions in cancer treatment, diagnostics, and patient care. By supporting innovators like Nine Diagnostics, BrightEdge aims to bridge the gap between pioneering research and commercial success, ensuring that the most promising oncology technologies reach the patients who need them most.
This selection builds on Nine Diagnostics’ growing portfolio of strategic partnerships and accelerator engagements, including its acceptance into the Merck Digital Sciences Studio and the 2024 Novo Nordisk Golden Ticket, solidifying its position as a leader in next-generation cancer diagnostics, tools, and technologies.
About Nine Diagnostics
Nine Diagnostics is an AI-enabled multi-omic nanosensor company advancing precision medicine. The platform simultaneously captures proteomic, metabolomic, and lipidomic signals alongside patient clinical context to generate a multi-omic fingerprint, using machine learning to identify disease-relevant patterns without requiring prior knowledge of which biomarkers matter. This enables pre-treatment patient stratification, on-treatment response monitoring, and post-treatment minimal residual disease detection. Founded by Freddy T. Nguyen, MD, PhD (Co-Founder and CEO), Daniel A. Heller, PhD (Co-Founder and CSO), and Mijin Kim, PhD (Co-Founder and Scientific Advisor), Nine Diagnostics is based in Cambridge, Massachusetts.